Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01814826 · ClinicalTrials.gov registry record · Phase 1
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01814826 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT01814826, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60 years of age or older.
Interventions
- DRUG Azacitidine
- DRUG MLN4924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-04-10 |
| Est. Completion | 2018-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01814826
The ClinicalTrials.gov registry entry for NCT01814826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT01814826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01814826 about?
NCT01814826 is a clinical study titled "Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older". The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60 years of age or older.
What is the current status of trial NCT01814826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-04-10. Estimated completion is 2018-04-08.
What interventions are being tested in trial NCT01814826?
The interventions under investigation include: Azacitidine (DRUG), MLN4924 (DRUG).
Who is sponsoring clinical trial NCT01814826?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.